Carmustine Sustained-Release Implant Wafer

A sustained release (SR) implant wafer containing the lipophilic nitrosourea carmustine (BCNU) with antineoplastic activity. Upon intracranial administration of the implant wafer and subsequent release of BCNU from the wafer, this agent alkylates and cross-links DNA during all phases of the cell cycle, resulting in the disruption of DNA function, cell cycle arrest, and apoptosis. This wafer contains the biodegradable copolymer PLGA (poly(lactide-co-glycolide) as the major drug delivery vehicle which is slowly degraded into water and carbon dioxide thereby continously releasing BCNU over approximately 3-4 weeks. Compared to systemic administration of BCNU alone, this local SR formulation is able to maintain higher drug concentrations locally over a longer period of time while minimizing exposure to other tissues. (NCI Thesaurus)

YOU MAY ALSO LIKE

Carmustine in Ethanol

A formulation containing carmustine dissolved in ethanol for intra-tumoral administration that allows carmustine to enter both aqueous and lipid compartments of the…

Carmustine implant

A biodegradable wafer that is used to deliver the anticancer drug carmustine directly into a brain tumor site after the tumor has…

Carmustine

An anticancer drug that belongs to the family of drugs called alkylating agents.

Carmofur

An antimetabolite (pyrimidine analogue) antineoplastic derivative of 5-fluorouracil.

Carmegliptin Dihydrochloride

The dihydrochloride salt form of carmegliptin, a potent, long-acting, selective, orally bioavailable, pyrrolidinone-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic…

Carmegliptin

A potent, long-acting, selective, orally bioavailable, pyrrolidinone-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Carmegliptin shows extensive tissue distribution and…